Novo Nordisk CEO Mike Doustdar bluntly stated pharma is only scratching the surface of the massive weight-loss drug market, targeting the 110 million obese Americans. He emphasized the need to expand access, noting Novo, Eli Lilly, and compounding pharmacies collectively reach less than 10-15% of that population. Doustdar's comments came as Novo seeks to regain market lead lost to Lilly and recover from recent setbacks.

A key strategy involves significant price cuts: a 50% wholesale price reduction for Wegovy and 35% for Ozempic starting January, alongside a TrumpRx deal. However, patent expiries in major markets like Canada, India, Brazil, and China pose a major threat, allowing generic competition. India, with its price-sensitive market, already sees 10+ companies launching generics.

Novo is responding with partnerships (e.g., Eurofarma in Brazil, Emcure in India) and price cuts (up to 37% in India), but faces the fundamental challenge that the weight-loss drug market remains tiny compared to diabetes treatments in many regions. Doustdar stressed brand trust and quality are crucial to compete with generics.